Summit Therapeutics (SMMT) Receives a Hold from Oppenheimer
Oppenheimer analyst Hartaj Singh maintained a Hold rating on Summit Therapeutics (SMMT) today. The company’s shares opened today at $1.88, close to its 52-week low of $1.10.
According to TipRanks.com, Singh is a 3-star analyst with an average return of 3.1% and a 47.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Summit Therapeutics is a Moderate Buy with an average price target of $2.
See today’s analyst top recommended stocks >>
Based on Summit Therapeutics’ latest earnings release for the quarter ending October 31, the company reported a quarterly GAAP net loss of $10.55 million. In comparison, last year the company had a GAAP net loss of $15.53 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection.